

NCIC CLINICAL TRIALS GROUP

**GENITOURINARY**

DISEASE SITE COMMITTEE MEETING

AGENDA

Delta Chelsea Hotel, Toronto, Ontario  
Saturday, April 28, 2007 - 9:00 a.m. - 3:30 p.m.  
Room: ROSSETTI

Chair: Martin Gleave

---

9:00 a.m.	Welcome, Approval of Fall Meeting Minutes and Chairman's report	M. Gleave
9:10 a.m.	<b>NCIC CTG PHASE III TRIALS: OPEN</b> PR.8 BL.8 / EORTC 30994 BL.11	B. Donnelly L. Wood / A. Aprikian L. Lacombe
9:40 a.m.	<b>NCIC CTG PHASE III TRIALS: CLOSED</b> PR.7/PR.7 bone sub study PR.3 PRP.1 PRP.1B – open to accrued patients BL.7 (EORTC 30987)	J. Crook / L.Klotz P. Warde N. Fleshner N. Fleshner E. Winquist / M. Moore
9:50 a.m.	<b>NCIC CTG PHASE III TRIALS: APPROVED / PENDING ACTIVATION</b> PR.11 PR.12 PR.13 (RADICALS)	L. Klotz M. McKenzie / K. Chi C. Catton / C. Morash
10:05 a.m	<b>CTSU TRIALS ENDORSED BY NCIC CTG</b> CALGB 90202 HT with or without zoledronic acid in hormone naïve met CaP ECOG 2805 Sunitinib, Surafanib and Placebo in resected renal cell ca	F. Saad M. Jewett / L. Wood
	<b>CTSU TRIALS PENDING ENDORSEMENT</b> CALGB 90203	M. Gleave
10:20 a.m.	<b>BREAK</b>	
10:40 a.m.	<b>NCIC CTG IND TRIALS</b> IND.154 Phase I OGX-011 + Taxotere (closed) IND.161 Triapine Phase II (closed) IND.165 Randomized Phase II (OGX-011 +/- docetaxel HRPC) (closed) IND.167 (BAY 43-9006 prostate) (closed)	K. Chi J. Knox K. Chi K. Chi

*continued . .*

- 11:00 a.m. **OPEN CUOG TRIALS**
- |            |   |                           |
|------------|---|---------------------------|
| CUOG-R-05  | Role of Delayed Treatment for Early Stage RCCa  | M. Jewett                 |
| CUOG-P-05  | RCT Risedronate vs Placebo for the Prevention of Androgen Deprivation Bone Loss in Non-Metastatic Prostate Cancer | F. Saad                   |
| CUOG/CURC  | CHICS Trial   | L. Klotz                  |
| CUOG P-06a | Phase III trial of docetaxel +/- high dose Calcitriol   | K. Chi                    |
| ATLAS 3501 | Taxotere Adjuvant Trial (Aventis)   | D. Drachenberg / S. North |
| CUOG P-06c | Phase II Study of OGX-011 + mitoxantrone vs OGX-011+ docetaxel as A 2nd Line Chemotherapy in HRPC                 | F. Saad / E. Winquist     |
| CUOG P-06b | Phase II Study of Patupilone (Epo906a) As A 2nd Line Therapy in HRPC  | K. Chi                    |
- 12:00 a.m. **LUNCH**
- 1:00 p.m. **PENDING CUOG TRIALS**
- |  |   |                    |
|--|---|--------------------|
|  | Sutent as salvage therapy in NSGCT              | C. Kollmannsberger |
|  | IAS Plus dutasteride in PSA failures            | F. Saad            |
|  | ELAAT – early vs Late Androgen Ablation Therapy | A. Loblaw          |
- 1:40 p.m. **CLOSED CUOG TRIALS**
- |   |  |             |
|---|--|-------------|
| CUOG P-01b (NHT Taxotere)   |  | M. Gleave   |
| Taxotere as Second Line in HRPC                                       |  | F. Saad     |
| Iressa for Rising PSA post RP   |  | L. Klotz    |
| CUOG B-05 BMS/CUOG second line bladder trial with vinflunine (closed) |  | E. Winquist |
- 2:00 p.m. **TRIALS UNDER DEVELOPMENT**
- CUOG**
- |   |  |                   |
|---|--|-------------------|
| Phase II study of SU011248 for maintenace therapy in HRPC after 1st line chemotherapy   |  | B. Eigll          |
| Second-line bladder study (single arm Abraxane)   |  | Y. Ko             |
| Randomized, placebo-controlled phase II study of SU011248 plus best supportive care (BSC) versus placebo <u>plus BSC</u> in patients with advanced urothelial carcinoma who have failed cisplatin containing chemotherapy |  | T. Cheng          |
| Temsirolimus second line RCC trial in sutent failure  |  | F. Saad / L. Wood |
- 3:15 p.m. **OPEN DISCUSSION - NEW BUSINESS, STRATEGIC PLANNING INCLUDING NCI US GRANT APPLICATION**
- 3:30 p.m. **GU EXECUTIVE (CLOSED)**